Lilly Oncology To Unveil More Than 50 Studies At Asco 2008

Main Category: Cancer / Oncology
Article Date: 07 May 2008 - 4:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Eli Lilly and Company will unveil data from more than 50 studies at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. from May 30 to June 3, 2008. The company will present the latest research findings on ALIMTA® (pemetrexed for injection), GEMZAR® (gemcitabine HCl for injection), and enzastaurin, an investigational, oral, targeted therapy. The majority of the studies being presented are findings that support Lilly's leadership in thoracic cancer research.

Of note is a pivotal Phase III study (ASCO Abstract # 8060) that demonstrated a key correlation between lung cancer histology (tissue type), treatment choice and patient outcome. It will be one of the studies featured on Thursday, May 15 in ASCO's live online presscast. The virtual press event will be the first time ASCO has selected researchers to present key abstracts prior to its annual meeting.

"Improved patient outcomes via tailored therapy continues to be our focus and this year's ASCO is no exception," said Richard Gaynor, M.D., Lilly vice president, cancer research and global oncology platform leader. "With Lilly studies focusing on thoracic and breast cancer, among others, this meeting will continue to show our commitment to answering the unmet needs of cancer care."

Key Pemetrexed Abstracts for ASCO 2008:

-- Abstract # 8060: June 2, 2008; 3:00 p.m.
- Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study
- This study will be featured during ASCO presscast on May 15

-- Abstract # 8096: June 1, 2008; 2:00 p.m.
- Comparison of patient outcomes stratified by histology among pemetrexed-treated patients with stage IIIB/IV NSCLC in two Phase II trials

-- Abstract # 8097: June 1, 2008; 2:00 p.m.
- Resource utilization by non-small cell lung cancer histology: Results from the randomized, phase III trial of pemetrexed/cisplatin versus gemcitabine/cisplatin


Lilly Oncology